CME credits were approved by the Mercer Medical School   Mercer

Cancer Biology and Immunotherapy

Savannah, Georgia | March 30-April 01, 2020
Venue: The DeSoto Savannah | Savannah, GA 31401, USA

Plenary Speakers

Conference Schedule

Monday March 30, 2020

  • 8:30-9:00 Welcome and Introductions

  • Plenary Session 1: Cancer biology, pathology and metastasis

  • 9:00-9:40 Dr. J J O’leary, Trinity College, Dublin, Ireland
  • Cancer pathology and tumor growth kinetics, metastasis and tumor cell-stroma relationships

  • 9:40-10:20 Dr. Heyu Ni, University of Toronto, Toronto, Canada
  • The role of blood platelets in cancer metastasis

  • 10:20-10:50Coffee Break

  • 10:50-11:30 Dr. Michael Hwang, Johns Hopkins Medical Institute, Baltimore, MD
  • Mutations in oncogenes and tumor suppressor genes drive tumorigenesis: MANA bodies TCR-mimic antibodies for cancer therapy

  • 11:30-12:10 Dr. Shruti Naik, NYU Langone Center, New York
  • Two to tango: dialogue between immunity and stem cells in health and disease

  • 12:10-01:00 Panel Discussion

  • 1:00-2:00 Lunch

  • Plenary Session 2: Passive immunotherapy

  • 2:00-2:40 Dr. Jason David Howard, Sanofi-Genzyme, Cambridge, MA
  • Passive immunotherapy in advanced disease cancer patients

  • 2:40-3:20 Dr. Christopher E. Rudd, University of Montreal, Quebec, Canada
  • GSK-3 Inactivation synergizes with PD-1/PL1 and CTLA-4 blockade in cancer immunotherapy

  • 3:20-3:50Coffee Break

  • 3:50-4:30 Dr. Michael Lotze, UPMC Hillman Cancer Center, Pittsburgh, PA
  • Adoptive cell therapies for cancer: focus on tumor infiltrating lymphocytes

  • 4:30-5:10 Dr. Ugo Rovigatti, University of Florence, Italy
  • From anti-GD2 passive immunotherapy in High-Risk Neuroblastoma (HR-NBL) to a new landscape of genomic aberrations and immunotherapy targets

  • 5:10-5:50 Dr. Keith Knutson, Mayo Clinic, Jacksonville, FL
  • Immunotherapy beyond checkpoint

  • 5:50-6:30 Panel discussion

Tuesday March 31, 2020

  • Plenary Session 3: Cancer immunoprevention

  • 8:30-9:10 Dr. Hideho Okada, University of California San Francisco, CA
  • Vaccine approaches for patients with low-grade glioma aimed at prevention of malignant transformation

  • 9:10-9:50 Dr. Vincent K. Tuohy, Cleveland Clinic, Lerner Institute, Cleveland Ohio
  • Primary immunoprevention of adult onset cancers

  • 9:50-10:30 Coffee Break

  • 10:30-11:10 Dr. Olivera Finn, University of Pittsburgh, Pittsburgh, PA
  • Vaccines for the prevention of non-viral cancers

  • 11:10-12:00 Panel discussion

  • 12:00-1:00 Lunch

  • Plenary Session 4: Active specific immunotherapy

  • 1:00-1:40 Dr. Julie Magarian Blander, Cornell University, New York, NY
  • Innate immunity in immunotherapy, macrophages and dendritic cells

  • 1:40-2:20 Dr. Robert Dillman, AIVITA Biomedical, Irvine, CA
  • Evolution of therapeutic cancer vaccines

  • 2:20-3:00 Dr. Michael G. Hanna Jr., Per-Immune Inc., Savannah, GA
  • Personalized cancer vaccines: design and clinical application

  • 3:00-3:30Coffee Break

  • 3:30-4:10 Dr. J. Milburn Jessup, Veterans Administration Medical Center, Washington, DC
  • Immunogenic cell death is an agnostic adaptive immunity primer for solid tumors

  • 4:10-4:50 Dr. Martin D’Souza, School of Pharmacy, Mercer Medical School, Atlanta, GA
  • Cancer nano-vaccines delivered via “Band-Aid Like” microneedle patches

  • 4:50-6:00 Panel Discussion

Wednesday April 1, 2020

  • Plenary Session 5: Cancer immunotherapy monitoring, methodology and drug design

  • 8:30-9:10 Dr. Peter Nara, Keystone Bio Inc., St. Louise, MO
  • Cancer treatment monitoring and drug design

  • 9:10-9:40 Dr. Richard G. Pestell, Pennsylvania Cancer and Regenerative Medicine Center, PA
  • Cancer Stem cells (CSC). Genetic drivers and therapeutic targeting via a new receptor

  • 9:40-10:10 Dr. F. Guiakhoo, GeoVax Inc. Atlanta, GA
  • MVA-VLP as a safe and effective platform for delivery of multi-antigen vaccine candidates for infectious diseases and cancer

  • 10:10-10:30 Coffee Break

  • 10:30-11:00 Dr. Joana Roder, Biodesix, Boulder, CO
  • Application of machine learning to proteomic datasets: What can AI tell us about immune phenotypes from measurements of the circulating proteome?

  • 11:00-11:30 Dr. Karen A. Norris, University of Georgia, Athens, GA Immunity and immunization in the immunocompromised host

  • 11:30-12:00 Panel Discussion

  • 12:00-1:30 Lunch and Meeting Closure

About CBI-2020

To date, the passive immunotherapeutic approaches which have been FDA-approved clearly provide clinical benefit to a proportion of advanced disease patients. While these treatments have been heralded as much needed improvements, the nearly 600,000 Americans who died of cancer last year did not gain the level of benefit we would have hoped from modern cancer care. As the frontiers of cancer immunotherapy are pushing forward, we need to concentrate on integrative translational medicine. We are proposing to have an outlet for a comprehensive discussion, which will simultaneously integrate a deep understanding of the biology of cancer along with the development of future treatment concepts to ultimately realize the full potential of this clinical revolution.

Learn more
about image

About Janus

JanusJanus was the Roman god of beginnings and transitions. It is depicted as a two-faced image that looks to the future and the past. As first pointed out by Dr. Olivera Finn, the Janus principle can be used to illustrate the past accomplishments and future opportunities in Immunotherapy of Cancer. In this case, immune function/tumor rejection and immune dysfunction/tumor progression. Ann Oncol 2012 Sep 23 (Suppl 8).


Early Bird